ClinicalTrials.gg
RecruitingNCT06574568Updated Feb 5, 2026

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of YKST02 in Relapsed or Refractory Multiple Myeloma, sponsored by Excyte Biopharma Ltd. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Excyte Biopharma Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
147th of 406
70 · median 40
Started
2024
with 46 others
Phase 1
151 of 448
73 open now
Primary completion
2026-12
later than 110 of 274 live
Registered
316th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 147th largest by planned enrollment of the 406 interventional ones that give a count, is one of 47 that started in 2024, is one of 151 in phase 1, reaches primary completion later than 110 of the 274 other live ones, and was the 316th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.

Read the detailed description

This study is the first-in-human clinical trial to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of YKST02 in patients with relapsed or refractory multiple myeloma (MM). Multiple Myeloma (MM) is a cancer of the blood's plasma cells (blood cell). YKST02 is a bispecific antibody bridging CD3-expressing T cells and BCMA-expressing multiple myeloma cells to induce T cells-mediated cytotoxicity. This study consists of dose escalation phase and dose expansion phase.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's planned enrollment of 70 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Excyte Biopharma Ltd is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants or their legally acceptable representative must sign an ICF indicating that the participants understand the purpose of, and procedures required for the study and are willing to participate in the study.
  2. Diagnosis of multiple myeloma according to the IMWG criteria.
  3. Receipt of at least two prior classes of drugs either in separate regimens or as combinations. The three classes are defined as: An immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug.
  4. at screening, as defined by at least 1 of the following:

    1. Serum M-protein ≥0.5 g/dL;
    2. Urinary M-protein excretion ≥200 mg/24 hours;
    3. Abnormal serum free light chain (FLC) ratio ( \<0.26 or >1.65) and serum immunoglobulin FLC≥10 mg/dL.
  5. Performance Status (ECOG) of 0-1.
  6. An estimated survival time of more than 12 weeks.
  7. Recovery to Grade 0-1 (Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events () Version (v) 5.0) from adverse events related to prior therapy except alopecia.
  8. Adequate hematological and organ function.
  9. Female participants of must have a negative serum pregnancy test at screening. Female patients who are sexually active must use highly effective methods of throughout the study and for 3 months following the last dose of study treatment.
  10. Male participants must agree to use reliable methods of contraception (barrier methods or sexual abstinence) and avoid sperm donation throughout the study period and until 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Plasma cell leukemia (>2.0×10\^9/L plasma cells by standard differential), Waldenstrom's Macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary light-chain amyloidosis.
  2. History of antitumor therapy as follows, before the first dose of study drug:

    1. Targeted therapy with small molecule drug within 2 weeks or 5 half-lives, whichever is longer;
    2. Targeted therapy with macromolecular drug or Immunomodulatory agent therapy within 2 weeks;
    3. Chemotherapy within 2 weeks;
    4. Treatment with an drug within 2 weeks or 5 half-lives, whichever is shorter;
    5. Radical/extensive radiotherapy within 4 weeks, or local palliative radiotherapy within 2 weeks, or acute toxicity induced by previous radiotherapy have not recovered to grade ≤1;
    6. stem cell transplantation within 12 weeks;
    7. History of organ transplant, or allogeneic stem cell transplantation within 6 months;
    8. Prior treatment with any B cell maturation antigen (BCMA) targeted therapy;
    9. Prior treatment with any BCMA targeted chimeric antigen receptor modified [CAR]-T cells therapy.
  3. Any active acute (GvHD), grade 2-4 (according to Glucksberg criteria) or active chronic GvHD requiring systemic treatment within 2 weeks.
  4. Prior myelodysplastic syndrome or within 5 years, except for localized malignancies that have been adequately treated or free of the disease for ≥ 5 years, e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-muscle invasive bladder cancer, localized prostate cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast.
  5. Active central nervous system (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma, or other evidence of uncontrolled to the CNS or meninges, judged by the investigator.
  6. (a) History of or current relevant CNS pathology as epilepsy, seizure, paresis, aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis; (b) Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI.
  7. History or evidence of cardiovascular disease, including:

    1. Acute coronary syndromes (eg, myocardial infarction, unstable angina) within 6 months prior to enrollment;
    2. Coronary angioplasty or stenting within 6 months prior to enrollment;
    3. unstable arrhythmias (eg, atrial fibrillation), however, atrial fibrillation has been controlled for over 30 days prior to the first dose of YKST02 were allowed;
    4. (NYHA) stage III or higher congestive heart failure within 6 months prior to enrollment; Cardiac valve morphological abnormalities recorded by ECHO (≥ grade 2), note that grade 1 cardiac valve morphological abnormalities (such as mild regurgitation/stenosis) were allowed, but participants with moderate valve thickening were excluded;
    5. (LVEF) below lower limit of the study center, or LVEF\<50% if there is no lower limit at the study center;
    6. The Fridericia- interval (QTcF) ≥ 470 msec (female) or ≥ 450 msec (male);
    7. Implantable defibrillator;
    8. Clinically uncontrollable hypertension (i.e., SBP≥160 mm Hg and/or DBP≥100 mm Hg).
  8. Known allergy to monoclonal antibody drugs or exogenous immunoglobulin.
  9. Any major organ surgery or significant trauma within 4 weeks prior to the first dose of YKST02, or those requiring elective surgeries during the study, and all AEs associated with surgery or significant trauma have not recovered before the first dose of the YKST02.
  10. Regular dose of systemic during 4 weeks prior to initiation of study drug, or anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent during the trial, or any other systemic therapy within 4 weeks prior to study entry.
  11. Virological tests: virus surface antigen (HBsAg) positive and/or hepatitis B core antibody (HBcAb) positive, and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) quantitative > of the testing institution; antibody (HCV-Ab) positive and hepatitis C virus-RNA (HCV-RNA) quantitative > ULN of the testing institution; Anti- (Anti-HIV) positive. Participants will be excluded from the study if any of the above criteria is met.
  12. Uncontrolled active infections requiring oral or intravenous systemic therapy, except for local treatment.
  13. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently).
  14. Pregnant or lactating women.
  15. Known mental disorder that may affect study compliance or poor compliance.
  16. Receipt of any or live virus vaccine within 4 weeks prior to the first dose of study treatment.
  17. Other serious systemic diseases or laboratory abnormalities or other reasons that the investigator believes are not appropriate for participating the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    YKST02

    Participants will receive different doses of YKST02 in 21-day cycles via intravenous injection.

    Drug: YKST02

Interventions

  • DrugYKST02

    BCMA-CD3 bispecific antibody

    Also known as: YKST02 for Injection

07

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-limiting Toxicities (DLT)

    The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and are specifically defined in study protocol.

    Time frame: 21 days after the first dose

  2. Incidence of Adverse Events (AEs)

    An AE is defined as any untoward medical event that occurs after a subject receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the investigational drug.

    Time frame: up to 42 weeks

  3. Incidence of Serious Adverse Events (SAEs)

    A SAE refers to an untoward medical occurrence such as death, life-threatening event, permanent or serious disability or loss of function, need for hospitalization or prolongation of hospitalization after the subject receives the investigational drug, and congenital abnormalities or birth defects.

    Time frame: up to 42 weeks

  4. Overall Response Rate (ORR)

    Measured by IMWG criteria, only applicable in dose expansion phase

    Time frame: From the date of dosing until the date of first documented progression

Secondary outcomes

  1. Area under the Concentration-time Curve (AUC) after Administration

    AUC of YKST02

    Time frame: up to 42 weeks

  2. Maximum Serum Concentration (Cmax) of YKST02

    Cmax is defined as the maximum observed serum concentration of YKST02

    Time frame: up to 42 weeks

  3. Time to Cmax of YKST02 (Tmax)

    Time to maximum serum concentration (Tmax) of YKST02

    Time frame: up to 42 weeks

  4. Terminal Half-life (T1/2) of YKST02

    Terminal Half-life (T1/2) of YKST02

    Time frame: up to 42 weeks

  5. Percentage of Participants with Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab) Against YKST02

    Assess the percentage of participants with ADA and Nab (only assessed when ADA positive) after treatment with YKST02.

    Time frame: up to 42 weeks

  6. ORR

    Measured by IMWG criteria, only applicable in dose escalation phase

    Time frame: From the date of dosing until the date of first documented progression

  7. Progression-free Survival (PFS)

    Evaluation of the efficacy of YKST02 in patients with MM on progression-free survival

    Time frame: From the date of dosing until the date of first documented progression

  8. Overall survival (OS)

    Overall survival (OS) was defined as the time from the date of first dose until death due to any cause.

    Time frame: From the date of first dose until loss of follow-up, death, withdrawal of informed consent, or the end of study, whichever occurs first

  9. Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate was the percentage of participants with CR/sCR and negative MRD.

    Time frame: From start of treatment to end of the study (approximately 42 weeks)

08

Study locations

7 of 12 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 30 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 28, 2024
StartActual
Jun 14, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06574568
Lead sponsor
Excyte Biopharma Ltd
Responsible party
Sponsor
First posted
Aug 28, 2024
Start date
Jun 14, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Wenming Chen, MD
Contact
13910107759@163.com
+86-13910107759
Wenming Chen, MD
principal investigator · Beijing Chao Yang Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YKST02

Start the discussion